BioCardia, Inc.

BCDA

Healthcare|Biotechnology|US

$0.85

-0.04 (-4.49%)

DCF Value

$0.21

Tangible Book / Share

$0.22

Cash / Share

$0.34

Next Earnings Report

Nov 11, 2026

EPS est. -$0.15

Financing Filings (last 12 months)

No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (2)

Dec 2026

Est. completion

P1P2Heart Failure, Systolic

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

NCT05925608n=39

Apr 2027

Est. completion

NAIschemic Heart Failure

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

NCT06258447n=250

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Feb 2025

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

NCT03455725

Recent Press Releases

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application

Nov 6, 2026 · GlobeNewsWire

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

Oct 19, 2026 · GlobeNewsWire

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

Oct 7, 2026 · GlobeNewsWire

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

Oct 1, 2026 · GlobeNewsWire

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

Sep 23, 2026 · GlobeNewsWire

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026 · GlobeNewsWire

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

Aug 24, 2026 · GlobeNewsWire

SEC Filings (94)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 6, 2026	8-K	Material event	Document Index
Oct 19, 2026	8-K	Material event	Document Index
Oct 7, 2026	8-K	Material event	Document Index
Oct 1, 2026	8-K	Material event	Document Index
Sep 23, 2026	8-K	Material event	Document Index
Sep 21, 2026	8-K	Material event	Document Index
Sep 10, 2026	8-K	Material event	Document Index
Aug 24, 2026	8-K	Material event	Document Index
Aug 21, 2026	8-K	Material event	Document Index
Aug 12, 2026	8-K	Material event	Document Index
Aug 12, 2026	10-Q	Quarterly report	Document Index
Jun 18, 2026	8-K	Material event	Document Index
Jun 12, 2026	8-K	Material event	Document Index
Jun 8, 2026	8-K	Material event	Document Index
Jun 5, 2026	8-K	Material event	Document Index
May 28, 2026	8-K	Material event	Document Index
May 21, 2026	8-K	Material event	Document Index
May 15, 2026	8-K	Material event	Document Index
May 15, 2026	10-Q	Quarterly report	Document Index
May 8, 2026	8-K	Material event	Document Index
Apr 28, 2026	8-K	Material event	Document Index
Apr 20, 2026	8-K	Material event	Document Index
Apr 15, 2026	8-K	Material event	Document Index
Apr 2, 2026	8-K	Material event	Document Index
Mar 24, 2026	8-K	Material event	Document Index
Mar 24, 2026	S-8	Employee stock plan	Document Index
Mar 24, 2026	10-K	Annual report	Document Index
Mar 17, 2026	8-K	Material event	Document Index
Mar 3, 2026	8-K	Material event	Document Index
Feb 10, 2026	8-K	Material event	Document Index
Feb 3, 2026	8-K	Material event	Document Index
Dec 18, 2025	S-8	Employee stock plan	Document Index
Dec 16, 2025	8-K	Material event	Document Index
Dec 3, 2025	8-K	Material event	Document Index
Nov 12, 2025	8-K	Material event	Document Index
Nov 12, 2025	10-Q	Quarterly report	Document Index
Nov 10, 2025	8-K	Material event	Document Index
Nov 3, 2025	DEF 14A	Proxy / shareholder vote	Document Index
Oct 30, 2025	8-K	Material event	Document Index
Oct 29, 2025	10-Q/A	Quarterly report	Document Index